“Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer”
Patients with hormone sensitive oligometastatic prostate cancer (a?$ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with intermittent androgen deprivation therapy +/- chemotherapy, stereotactic radiotherapy to all metastases, and either radical prostatectomy or radiotherapy.
Procedure - Radical prostatectomy
Radiation - HDR (19Gy) or SBRT (35-40Gy)
Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
Randomized Feasibility Trial of Prostate Radiotherapy vs Prostatectomy in Men With Hormone Sensitive Oligometastatic Prostate Cancer